Results 291 to 300 of about 14,964,075 (408)

Circulating tumor DNA monitoring and blood tumor mutational burden in patients with metastatic solid tumors treated with atezolizumab

Molecular Oncology, EarlyView.
In patients treated with atezolizumab as a part of the MyPathway (NCT02091141) trial, pre‐treatment ctDNA tumor fraction at high levels was associated with poor outcomes (radiographic response, progression‐free survival, and overall survival) but better sensitivity for blood tumor mutational burden (bTMB).
Charles Swanton, Russell W. Madison, Candice Francheska B. Tambaoan, Funda Meric‐Bernstam, Christopher J. Sweeney, Razelle Kurzrock, Howard A. Burris III, David R. Spigel, Hanna Tukachinsky, Jason Hughes, Julia Malato, Bongin Yoo, Tania Szado, Cheryl Schwab, Lincoln W. Pasquina, Amaya Gasco, Katja Schulze, Claire F. Friedman   +17 more
wiley   +1 more source

The impact of CD3ζ ITAM multiplicity and sequence on CAR T-cell survival and function. [PDF]

Front Immunol
Majumdar S, Echelibe H, Bettini M, Bettini ML.   +3 more
europepmc   +1 more source

X-ray excision repair replication and radiation survival in placental mammal cells

, 1976
John E. Byfield, Young C. Lee, Fimi Kulhanian   +2 more
openalex   +1 more source

Effect of ssbA1 and lexC113 mutations on lambda prophage induction, bacteriophage growth, and cell survival [PDF]

, 1980
L D Vales, John W. Chase, J B Murphy
openalex   +1 more source

Perk is essential for translational regulation and cell survival during the unfolded protein response.

Molecules and Cells, 2000
H. Harding, Yuhong Zhang, A. Bertolotti, Huiqing Zeng, D. Ron   +4 more
semanticscholar   +1 more source

Dose‐dependent induction of epithelial‐mesenchymal transition in 3D melanoma models by non‐thermal plasma treatment

Molecular Oncology, EarlyView.
Non‐thermal plasma treatment of melanoma cells induced epithelial‐mesenchymal transition (EMT) in a dose‐dependent fashion. This report highlights the critical need to further investigate potential adverse effects of non‐thermal plasma for cancer therapy and to optimize treatment parameters for clinical translation. Despite the promising results of non‐
Eline Biscop, Edgar Cardenas De La Hoz, Hanne Verswyvel, Joey De Backer, Ho Wa Lau, Angela Privat‐Maldonado, Wim Vanden Berghe, Steve Vanlanduit, Evelien Smits, Annemie Bogaerts, Abraham Lin   +10 more
wiley   +1 more source

SENP3-FIS1 axis promotes mitophagy and cell survival under hypoxia. [PDF]

Cell Death Dis
Zhao A, Maple L, Jiang J, Myers KN, Jones CG, Gagg H, McGarrity-Cottrell C, Rominiyi O, Collis SJ, Wells G, Rahman M, Danson SJ, Robinson D, Smythe C, Guo C.   +14 more
europepmc   +1 more source

Molecular imaging predicts trastuzumab‐deruxtecan (T‐DXd) response in head and neck cancer xenograft models

Molecular Oncology, EarlyView.
Trastuzumab‐deruxtecan, a HER2‐targeting antibody‐drug conjugate, shows promising antitumor activity in head and neck squamous cell carcinoma with low HER2 expression. In vitro and in vivo studies demonstrated dose‐dependent cell death and tumor growth reduction in low HER2‐expressing cell lines, which correlated with drug accumulation measured using a
Abdullah Bin Naveed, Lucas Mani, Muhammad Bilal Mirza, Ashtyn McAdoo, Takahito Kondo, Hidenori Tanaka, Nicole Meeks, Eben Rosenthal, Marisa Hom   +8 more
wiley   +1 more source

OTUD6B regulates KIFC1-dependent centrosome clustering and breast cancer cell survival. [PDF]

EMBO Rep
Marotta VE, Sabat-Pośpiech D, Fielding AB, Ponsford AH, Thomaz A, Querques F, Morgan MR, Prior IA, Coulson JM.   +8 more
europepmc   +1 more source

Prolonged survival time of allogeneic skin grafts in host pretreated with somatic cell hybrids and prednisolone.

, 1979
T Nishihira, Hiroshi Ishii, Morio Kasai, Takehiko Tachibana   +3 more
openalex   +2 more sources